News for Salarius Pharmaceuticals Inc Stock (SLRX)

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewsWire • 03/22/24

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

GlobeNewsWire • 01/03/24

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

GlobeNewsWire • 11/07/23

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

GlobeNewsWire • 08/10/23

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

GlobeNewsWire • 07/11/23

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

GlobeNewsWire • 06/12/23

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewsWire • 05/16/23

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewsWire • 05/12/23

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

GlobeNewsWire • 05/11/23

Salarius Pharmaceuticals stock soars premarket after FDA lifts partial clinical hold on trial of treatment for rare form of cancer that starts in childhood

Market Watch • 05/09/23

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

GlobeNewsWire • 05/09/23

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

GlobeNewsWire • 05/01/23

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

GlobeNewsWire • 04/20/23

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

GlobeNewsWire • 04/04/23

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewsWire • 03/27/23

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

GlobeNewsWire • 03/15/23

Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas

GlobeNewsWire • 02/16/23

Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

GlobeNewsWire • 01/27/23

Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit

GlobeNewsWire • 01/19/23

Investigators Present Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

GlobeNewsWire • 12/13/22

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

GlobeNewsWire • 12/13/22

Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas

GlobeNewsWire • 12/01/22

Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewsWire • 11/10/22

Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting

GlobeNewsWire • 11/03/22

Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference

GlobeNewsWire • 10/27/22